Kybernin P

Antithrombin III, the active ingredient in Kybernin P, is an antithrombin concentrate presented as an intravenous solution for intravenous use. It treats congenital antithrombin deficiency, supports anticoagulation during surgery such as cardiopulmonary bypass, and corrects acquired antithrombin deficiency in critically ill patients. It is indicated for patients with hereditary antithrombin deficiency, for peri‑operative anticoagulation in cardiac and vascular procedures, and for replacement therapy in intensive care settings where antithrombin levels are depleted.

GNH USA supplies Kybernin P as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, transplant centres, oncology centres, and pharmacies worldwide, ensuring quality‑controlled distribution and regulatory compliance.

Kybernin P, an antithrombin concentrate, is used to manage disorders of the coagulation cascade where antithrombin activity is insufficient.

- Congenital antithrombin deficiency: restores antithrombin levels to reduce thrombotic risk in patients with hereditary deficiency. - Peri‑operative anticoagulation (e.g., cardiopulmonary bypass): provides antithrombin supplementation to maintain anticoagulation during high‑risk surgeries. - Acquired antithrombin deficiency in critically ill patients: corrects depletion of antithrombin to support hemostatic balance in intensive care settings.

Kybernin P may be associated with adverse reactions, ranging from mild to severe.

Common Side Effects: - Hypersensitivity reactions: rash, itching, or urticaria. - Fever: transient elevation of body temperature. - Chills: shivering episodes during or after infusion. - Headache: mild to moderate intensity.

Serious or Rare Side Effects: - Anaphylaxis: severe allergic response requiring immediate medical intervention. - Thrombotic events: paradoxical clot formation despite anticoagulant therapy. - Hemolysis: destruction of red blood cells leading to anemia. - Renal impairment: decreased kidney function observed in rare cases.

When using Kybernin P, clinicians should observe several safety considerations.

- Dose adjustment in renal impairment: monitor antithrombin levels and renal function. - Monitor for hypersensitivity: observe patient during infusion for signs of allergic reaction. - Avoid concurrent use with heparin overdose: increased bleeding risk. - Use caution in patients with a history of thrombosis: assess risk‑benefit. - Pregnancy and lactation: safety not established; weigh potential benefits against risks. - Store at 2-8°C: keep refrigerated, protect from light, do not freeze or shake.

Kybernin P can interact with other medicines, requiring attention to potential additive effects.

Major Interactions (Avoid): - Heparin therapy: additive anticoagulant effect may cause bleeding. - Direct oral anticoagulants (DOACs): increased anticoagulation risk. - Antifibrinolytics (e.g., tranexamic acid): may counteract antithrombin effect.

Moderate Interactions (Monitor Closely): - Warfarin: may require INR monitoring. - Platelet inhibitors (aspirin, clopidogrel): monitor for bleeding. - Concomitant antibiotics that affect renal function: adjust dosing as needed.